Speaker illustration

Associate Professor Toshiyuki Nagai

Hokkaido University, Sapporo (Japan)

Member of:

European Society of Cardiology
Heart Failure Association

Currently, I lead a clinical heart failure research group whose work centers largely on clarifying the mechanisms of myocardial disease as well as proceeding outcome research. Projects cover a wide range of heart failure aspects and while my predominant focus is on the use of reginal / international heart failure registries, hemodynamic data, multimodality imaging and pathohistological data. Examples of areas include: 1) Heart failure: phenotyping in secondary care, developing precision medicine platform using registries and novel technologies (e.g., biomarkers, omics, genome, artificial intelligence). Invasive hemodynamic assessment using exercise right heart catheterization. Non-invasive hemodynamic assessment on the use of liver ultrasound and MR elastography. 2) Myocarditis, Cardiac sarcoidosis, Inflammatory cardiomyopathy: clarifying the mechanisms, risk stratification, therapies. 3) Structural heart disease: hemodynamic assessment on the use of 4D-flow MRI.

Low-dose administration of carperitide for Acute Heart Failure

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: Late breaking clinical trials: medical therapy

Thumbnail

High-density lipoprotein cholesterol does not predict future cardiovascular events in patients treated with statins for secondary prevention: an observation from the REAL-CAD study

Event: ESC Congress 2020

Topic: Secondary Prevention

Session: Deep Dive in Risk Factors and Prevention

Thumbnail

Effect of intravenous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure: insight from a nationwide claim-based database

Event: ESC Congress 2018

Topic: Pharmacotherapy

Session: Acute heart failure

Thumbnail

Impact of endogenous erythropoietin level on long-term clinical outcomes in patients with acute decompensated heart failure

Event: HEART FAILURE 2016

Topic: Prognosis (using biomarkers)

Session: Biomarkers

Thumbnail

High-density lipoprotein cholesterol does not predict future cardiovascular events in patients treated with statins for secondary prevention: an observation from the REAL-CAD study

Event: ESC Asia with APSC & AFC 2020

Topic: Secondary Prevention

Session: Abstract Programme

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb